Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Übersicht Suchergebnisse zum Thema DYNAVAX

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
12.03.DYNAVAX TECHNOLOGIES CORP - 8-K, Current Report3
23.02.Earnings call: Dynavax reports record revenue growth in 202314
22.02.DYNAVAX TECHNOLOGIES CORP - 10-K, Annual Report6
22.02.Dynavax Technologies: Q4 Earnings Insights10
22.02.DYNAVAX TECHNOLOGIES CORP - 8-K, Current Report3
22.02.Dynavax Technologies: Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance538HEPLISAV-B® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key segments retail pharmacy and IDNs in 2023 2024 HEPLISAV-B net product revenue expected...
► Artikel lesen
08.01.Dynavax reports 46% Y/Y increase in HEPLISAV-B vaccine net product revenue24
08.01.DYNAVAX TECHNOLOGIES CORP - 8-K, Current Report6
08.01.Dynavax Technologies: Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights333Preliminary full year 2023 HEPLISAV-B® vaccine net product revenue of approximately $213 million, a 69% year-over-year increase Significant gains in HEPLISAV-B market share in key market segments...
► Artikel lesen